BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34029636)

  • 21. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
    Rizzato M; Brignola S; Munari G; Gatti M; Dadduzio V; Borga C; Bergamo F; Pellino A; Angerilli V; Mescoli C; Guido M; Rearden J; Gringeri E; Cillo U; Dei Tos AP; Zagonel V; Loupakis F; Lonardi S; Fassan M
    Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
    Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
    Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10.
    Huijts PE; van Dongen M; de Goeij MC; van Moolenbroek AJ; Blanken F; Vreeswijk MP; de Kruijf EM; Mesker WE; van Zwet EW; Tollenaar RA; Smit VT; van Asperen CJ; Devilee P
    Breast Cancer Res; 2011 Jul; 13(4):R72. PubMed ID: 21767389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform.
    Cha JY; Maddileti S; Mitin N; Harden TK; Der CJ
    J Biol Chem; 2009 Mar; 284(10):6227-40. PubMed ID: 19103595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth.
    Amann T; Bataille F; Spruss T; Dettmer K; Wild P; Liedtke C; Mühlbauer M; Kiefer P; Oefner PJ; Trautwein C; Bosserhoff AK; Hellerbrand C
    Am J Pathol; 2010 Mar; 176(3):1433-42. PubMed ID: 20093481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishment and Long-Term Culture of Organoids Derived from Human Biliary Tract Carcinoma.
    Saito Y; Muramatsu T; Saito H
    STAR Protoc; 2020 Jun; 1(1):100009. PubMed ID: 33111070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FGFR2-CCDC6 fusion gene promotes the proliferation of Hucct-1 cells.
    Wang X; Li H; Zhang N; Wu T; Wang S
    Cell Mol Biol (Noisy-le-grand); 2022 Jun; 68(6):130-134. PubMed ID: 36227665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inducible Keratinocyte Specific FGFR2 Deficiency Inhibits UVB-Induced Signaling, Proliferation, Inflammation, and Skin Carcinogenesis.
    Thakur M; Rho O; Khandelwal A; Nathan CO; DiGiovanni J
    J Invest Dermatol; 2024 Feb; 144(2):341-350.e7. PubMed ID: 37660781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-sensitive FGFR2 mutations in endometrial carcinoma.
    Dutt A; Salvesen HB; Chen TH; Ramos AH; Onofrio RC; Hatton C; Nicoletti R; Winckler W; Grewal R; Hanna M; Wyhs N; Ziaugra L; Richter DJ; Trovik J; Engelsen IB; Stefansson IM; Fennell T; Cibulskis K; Zody MC; Akslen LA; Gabriel S; Wong KK; Sellers WR; Meyerson M; Greulich H
    Proc Natl Acad Sci U S A; 2008 Jun; 105(25):8713-7. PubMed ID: 18552176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth.
    Park J; Kim SY; Kim HJ; Kim KM; Choi EY; Kang MS
    Oncotarget; 2016 May; 7(19):28670-83. PubMed ID: 27107424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.
    Kim SY; Ahn T; Bang H; Ham JS; Kim J; Kim ST; Jang J; Shim M; Kang SY; Park SH; Min BH; Lee H; Kang WK; Kim KM; Park W; Lee J
    Oncotarget; 2017 Feb; 8(9):15014-15022. PubMed ID: 28122360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibroblast growth factor receptor 2 expression may be involved in transformation of ovarian endometrioma to clear cell carcinoma of the ovary.
    Taniguchi F; Itamochi H; Harada T; Terakawa N
    Int J Gynecol Cancer; 2013 Jun; 23(5):791-6. PubMed ID: 23640291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells.
    Moffa AB; Tannheimer SL; Ethier SP
    Mol Cancer Res; 2004 Nov; 2(11):643-52. PubMed ID: 15561780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance.
    Salm F; Cwiek P; Ghosal A; Lucia Buccarello A; Largey F; Wotzkow C; Höland K; Styp-Rekowska B; Djonov V; Zlobec I; Bodmer N; Gross N; Westermann F; Schäfer SC; Arcaro A
    Oncogene; 2013 Aug; 32(34):3944-53. PubMed ID: 23027129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling.
    Chen G; Qiu H; Ke SD; Hu SM; Yu SY; Zou SQ
    World J Gastroenterol; 2013 Apr; 19(16):2481-91. PubMed ID: 23674849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inactivation of Fgfr2 gene in mouse secondary palate mesenchymal cells leads to cleft palate.
    Jin JZ; Lei Z; Lan ZJ; Mukhopadhyay P; Ding J
    Reprod Toxicol; 2018 Apr; 77():137-142. PubMed ID: 29526646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells.
    Zhu X; Lee K; Asa SL; Ezzat S
    Am J Pathol; 2007 May; 170(5):1618-28. PubMed ID: 17456767
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Cleary JM; Raghavan S; Wu Q; Li YY; Spurr LF; Gupta HV; Rubinson DA; Fetter IJ; Hornick JL; Nowak JA; Siravegna G; Goyal L; Shi L; Brais LK; Loftus M; Shinagare AB; Abrams TA; Clancy TE; Wang J; Patel AK; Brichory F; Vaslin Chessex A; Sullivan RJ; Keller RB; Denning S; Hill ER; Shapiro GI; Pokorska-Bocci A; Zanna C; Ng K; Schrag D; Jänne PA; Hahn WC; Cherniack AD; Corcoran RB; Meyerson M; Daina A; Zoete V; Bardeesy N; Wolpin BM
    Cancer Discov; 2021 Oct; 11(10):2488-2505. PubMed ID: 33926920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.
    Krook MA; Bonneville R; Chen HZ; Reeser JW; Wing MR; Martin DM; Smith AM; Dao T; Samorodnitsky E; Paruchuri A; Miya J; Baker KR; Yu L; Timmers C; Dittmar K; Freud AG; Allenby P; Roychowdhury S
    Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 31371345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of fibroblast growth factor receptor 2 IIIc in human uterine cervical intraepithelial neoplasia and cervical cancer.
    Kawase R; Ishiwata T; Matsuda Y; Onda M; Kudo M; Takeshita T; Naito Z
    Int J Oncol; 2010 Feb; 36(2):331-40. PubMed ID: 20043066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.